w66国际·利来(中国)最给力的老牌

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024

VOLUNTARY ANNOUNCEMENT - RESULTS FROM PHASE IB/IIA CLINICAL STUDY OF FIRST-IN-CLASS JAK/ROCK INHIBITOR "ROVADICITINIB" PUBLISHED IN BLOOD

VOLUNTARY ANNOUNCEMENT - ENTERING INTO AN EXCLUSIVE COOPERATION AGREEMENT WITH DELOVA BIOTECH FOR QP001

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2025

CHANGE OF HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

NOTIFICATION OF BOARD MEETING

VOLUNTARY ANNOUNCEMENT - SIGNING OF AN EXCLUSIVE STRATEGIC COOPERATION AGREEMENT WITH SCIWIND BIOSCIENCES REGARDING PROJECT IL-29

VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF THE FIRST GENERIC “TULOBUTEROL PATCHES”